Yes, Jardiance is for diabetes — specifically type 2 diabetes. It is an FDA-approved oral SGLT2 inhibitor that lowers A1C by about 0.7 to 1.0 percent, supports modest weight loss, lowers blood pressure, and reduces the risk of cardiovascular events and kidney disease progression. It is also approved for heart failure and chronic kidney disease independent of diabetes. Jardiance is not approved for type 1 diabetes because of an elevated risk of euglycemic diabetic ketoacidosis.
What Jardiance Is
Jardiance is the brand name for empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved in 2014. It is taken as an oral tablet once a day. Its primary effect is to cause the kidneys to excrete glucose into urine, lowering blood sugar without requiring extra insulin or insulin sensitivity changes.
- Active ingredient — empagliflozin
- Class — SGLT2 inhibitor
- Form — oral tablet (10 mg, 25 mg)
- Frequency — once daily
- FDA-approved 2014 for type 2 diabetes; later indications for heart failure (2021) and CKD (2023)
What Jardiance Does for Blood Sugar
| Endpoint | Effect |
|---|---|
| A1C reduction (10 mg) | 0.7 to 0.8 percent |
| A1C reduction (25 mg) | 0.8 to 1.0 percent |
| Fasting plasma glucose | Drops 20 to 30 mg/dL |
| Postprandial glucose | Improves modestly |
| Weight loss | 2 to 3 kg over 24 weeks |
| Blood pressure | 3 to 5 / 2 mmHg reduction |
| Hypoglycemia (monotherapy) | Rare |
How It Works
- Blocks SGLT2 in the proximal tubule of the kidney
- Reduces glucose reabsorption by about 50 to 80 grams per day
- Excreted glucose carries calories — accounting for some of the weight loss
- Mild osmotic diuresis lowers blood pressure
- Effect is glucose-dependent — minimal hypoglycemia risk on its own
- Independent of pancreatic insulin secretion and insulin sensitivity
Who It Is For
- Adults with type 2 diabetes — to improve A1C with diet and exercise
- Type 2 diabetes plus established cardiovascular disease — to reduce CV events and mortality
- Type 2 diabetes plus heart failure — to reduce HF hospitalization
- Type 2 diabetes plus CKD — to slow progression
- People who would benefit from weight loss alongside glycemic control
- People at risk for hypoglycemia where insulin or sulfonylureas are problematic
Who Should Not Take It
- Type 1 diabetes
- History of severe hypersensitivity to empagliflozin
- Severe kidney impairment with eGFR less than 20 mL/min/1.73 m² (for HF and CKD indications)
- Active dialysis
- Recurrent genital or urinary tract infections
- History of euglycemic DKA on SGLT2 inhibitors
- Very-low-carbohydrate or ketogenic diet without DKA risk monitoring
Dose
- Start — 10 mg once daily in the morning
- Titrate — to 25 mg if additional glycemic effect needed and well tolerated
- HF or CKD — 10 mg only; no additional benefit from 25 mg
- With or without food
- Same time each day for consistency
- No renal dose adjustment until eGFR less than 20
Side Effects
| Side Effect | Frequency | What to Do |
|---|---|---|
| Genital yeast infection | 8 to 12 percent | Topical antifungal; usually does not require stopping |
| Urinary tract infection | 5 to 9 percent | Standard antibiotic treatment |
| Increased urination | 3 to 4 percent | Adjust fluid timing; typically improves |
| Dehydration / dizziness | 1 to 3 percent | Hydrate adequately; reduce diuretic if applicable |
| Mild LDL increase | About 5 mg/dL | Continue statin therapy |
| Euglycemic DKA | Less than 0.1 percent | Hold for illness or surgery; check ketones if symptomatic |
| Fournier gangrene | Very rare | Boxed warning — seek care for genital pain / redness |
Combining With Other Diabetes Medications
- Metformin — excellent combination; foundational first-line therapy plus Jardiance
- DPP-4 inhibitors (Januvia, Tradjenta) — complementary mechanism; Glyxambi is the fixed combination
- GLP-1 agonists (Ozempic, Trulicity, Mounjaro) — additive glycemic and weight loss benefit
- Sulfonylureas — combine with caution; reduce SU dose to limit hypoglycemia
- Insulin — common combination; insulin dose typically reduced 10 to 25 percent at SGLT2i start to lower DKA risk
- Thiazolidinediones (pioglitazone) — combination possible; watch for fluid retention from TZD offset by SGLT2i diuresis
Cardiovascular and Kidney Bonus
Beyond glycemic control, Jardiance offers benefits proven in landmark trials:
- EMPA-REG OUTCOME — 14 percent reduction in MACE (CV death, nonfatal MI, nonfatal stroke), 38 percent reduction in CV death, 35 percent reduction in HF hospitalization in T2D patients with established CV disease
- EMPEROR-Reduced — 25 percent reduction in CV death or HF hospitalization in HFrEF
- EMPEROR-Preserved — 21 percent reduction in similar endpoint in HFpEF
- EMPA-KIDNEY — 28 percent reduction in kidney disease progression or CV death in CKD
Monitoring
- A1C every 3 months until at goal, then every 6 months
- Kidney function (eGFR) at baseline and annually, more often if low
- Volume status, especially in the elderly or on diuretics
- Ketones if symptoms of DKA (nausea, vomiting, abdominal pain, fast breathing) — even at normal glucose
- Foot examination at routine visits
- Blood pressure with each visit, particularly first 1 to 2 months
Related Reading
For broader context, see our treatment hub and the A1C levels guide. For SGLT2 inhibitor class context, see Jardiance used for heart failure. For trial evidence, see the EMPA-REG OUTCOME trial.
The Bottom Line
Yes, Jardiance is for diabetes — specifically type 2 diabetes. It lowers A1C by about 0.7 to 1.0 percent, produces 2 to 3 kg of weight loss, modestly lowers blood pressure, and reduces cardiovascular and kidney complications. It is not approved for type 1 diabetes because of euglycemic ketoacidosis risk. Typical dose is 10 mg once daily, with the option to titrate to 25 mg for additional glycemic effect. Side effects include yeast and urinary infections, mild dehydration, and rare but serious euglycemic ketoacidosis. Talk to your doctor about whether Jardiance fits your diabetes management plan and overall cardiovascular and kidney risk picture.
